Characterization of nanoparticles encapsulating oligonucleotides for targeting endocytosis in nociceptors for the treatment of neuropathic pain
Active Awarded Last action
- Contract number
- 75N91023F00023
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,386,382
Award facts
- Contract value 100% obligated
- $2,386,382.00 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $383,255 | |
| Other Administrative Action | $361,328 | |
| Change Order | $1,046,318 | |
| Original award | $595,481 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 15, 2023, with a ceiling value of $2,386,382 for characterization of nanoparticles encapsulating oligonucleotides targeting endocytosis in nociceptors for neuropathic pain treatment. Place of performance is Frederick, MD. The order extends through September 14, 2028, under cost-plus-fixed-fee pricing with no set-aside designation.
Service Contract Inventory reporting shows minimal labor footprint: in FY2024, the most recent reported fiscal year, 0.1 FTEs were invoiced across 211 contractor hours at a derived government-paid rate of $63.36 per hour. Leidos Biomedical Research Inc. self-performed all reported hours with no subcontractors. FY2024 invoiced $13 thousand; FY2023 invoiced $15 thousand.
Quick answers
Who was awarded contract 75N91023F00023?
75N91023F00023 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00023 worth?
The government has obligated $2,386,382 on 75N91023F00023.
Which agency awarded contract 75N91023F00023?
National Cancer Institute (National Institutes of Health) awarded 75N91023F00023, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91023F00023 an order under another contract?
Yes. 75N91023F00023 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00023 competed?
The extent of competition for 75N91023F00023 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award